A detailed history of Voloridge Investment Management, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Voloridge Investment Management, LLC holds 353,323 shares of RYTM stock, worth $21.2 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
353,323
Previous 462,188 23.55%
Holding current value
$21.2 Million
Previous $19 Million 2.46%
% of portfolio
0.07%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.81 - $55.0 $4.44 Million - $5.99 Million
-108,865 Reduced 23.55%
353,323 $18.5 Million
Q2 2024

Aug 14, 2024

SELL
$35.41 - $44.37 $398,964 - $499,916
-11,267 Reduced 2.38%
462,188 $19 Million
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $4.33 Million - $5.81 Million
110,738 Added 30.53%
473,455 $20.5 Million
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $7.32 Million - $17 Million
342,350 Added 1680.91%
362,717 $16.7 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $322,002 - $566,202
20,367 New
20,367 $466,000
Q1 2023

May 15, 2023

SELL
$16.88 - $34.24 $23,733 - $48,141
-1,406 Reduced 0.72%
193,590 $3.45 Million
Q4 2022

Feb 14, 2023

SELL
$22.21 - $30.25 $1.08 Million - $1.46 Million
-48,412 Reduced 19.89%
194,996 $5.68 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $1.05 Million - $7.51 Million
243,408 New
243,408 $5.96 Million
Q1 2021

May 17, 2021

SELL
$20.25 - $39.49 $145,293 - $283,340
-7,175 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$21.17 - $32.61 $630,738 - $971,582
-29,794 Reduced 80.59%
7,175 $213,000
Q3 2020

Nov 16, 2020

BUY
$18.13 - $30.61 $670,247 - $1.13 Million
36,969 New
36,969 $801,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.